PRME (Prime Medicine) ROCE %: -71.88% (As of Mar. 2026)


PRME Prime Medicine Inc PRME
25 GF Score
Price $3.18
! 4 Warning Signs
View Full Analysis

What is Prime Medicine ROCE %?

Prime Medicine PRME +2.09% 25 ROCE % is -71.88% as of Mar. 2026. GuruFocus rates PRME with a GF Score™ of 25/100. The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Prime Medicine's annualized ROCE % for the quarter that ended in Mar. 2026 was -71.88%.

Prime Medicine  (NAS:PRME) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Prime Medicine ROCE % Related Terms

Prime Medicine ROCE % Historical Data

* Premium members only.

The historical data trend for Prime Medicine's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prime Medicine ROCE % Chart

Prime Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -60.51 -40.36 -81.22 -102.00 -73.77

Prime Medicine Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -75.74 -79.26 -72.58 -59.34 -71.88
PRME
25GF Score
Prime Medicine Inc PRME
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prime Medicine ROCE % Calculation

Prime Medicine's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-208.35/( ( (297.508 - 37.961) + (342.733 - 37.448) )/ 2 )
=-208.35/( (259.547+305.285)/ 2 )
=-208.35/282.416
=-73.77 %

Prime Medicine's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-202.616/( ( (342.733 - 37.448) + (294.73 - 36.289) )/ 2 )
=-202.616/( ( 305.285 + 258.441 )/ 2 )
=-202.616/281.863
=-71.88 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -71.88% mean?
Prime Medicine (PRME) has a ROCE % of -71.88% as of Mar. 2026.
Is Prime Medicine's ROCE % too high?
Prime Medicine's current ROCE % is -71.88%. Overall, Prime Medicine has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Prime Medicine's ROCE % compare to IMMX and SGP?
Prime Medicine's ROCE % of -71.88% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Prime Medicine's current ROCE % is -71.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prime Medicine stock overvalued right now?
Prime Medicine (PRME) has a current ROCE % of -71.88%. The current ROCE % is -71.88%. Prime Medicine's overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Prime Medicine (PRME), the current ROCE % is -71.88% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prime Medicine Business Description

Address 60 First Street, Cambridge, MA, USA, 02141
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
25GF Score

Get the complete analysis for PRME

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.18
Price